MedPath

SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. logo
🇨🇳China
Ownership
Joint Venture, Subsidiary
Established
2001-11-30
Employees
5K
Market Cap
-
Website
https://www.luoxin.cn

Clinical Trials

11

Active:0
Completed:9

Trial Phases

2 Phases

Phase 1:6
Phase 3:5

Drug Approvals

6

PHILIPPINES:6

Drug Approvals

Luoriaxon

Approval Date
Jul 14, 2025
PHILIPPINES

Luomepen

Approval Date
Jul 14, 2025
PHILIPPINES

Luozidime

Approval Date
Jul 14, 2025
PHILIPPINES

Luocitabin

Approval Date
Jul 14, 2025
PHILIPPINES

Luotaxime

Approval Date
Jul 14, 2025
PHILIPPINES

Luotriaxone

Approval Date
Jul 14, 2025
PHILIPPINES

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (54.5%)
Phase 3
5 (45.5%)

A Phase I Study of LX22001 for Injection in Healthy Subjects

Phase 1
Recruiting
Conditions
Healthy
Interventions
First Posted Date
2024-08-20
Last Posted Date
2024-08-20
Lead Sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Target Recruit Count
70
Registration Number
NCT06561542
Locations
🇨🇳

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-06-23
Last Posted Date
2023-06-23
Lead Sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Target Recruit Count
22
Registration Number
NCT05915871
Locations
🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans

Phase 1
Completed
Conditions
Healthy Subjects
Pharmacokinetics of 14C-labeled of LXI-15028
Interventions
Drug: [14C]LXI-15028
First Posted Date
2023-05-31
Last Posted Date
2023-05-31
Lead Sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Target Recruit Count
6
Registration Number
NCT05883306
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori

Phase 3
Completed
Conditions
Helicobacter Pylori Infection
Interventions
First Posted Date
2022-10-13
Last Posted Date
2024-01-10
Lead Sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Target Recruit Count
561
Registration Number
NCT05577468
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation

Phase 3
Completed
Conditions
Functional Constipation
Interventions
First Posted Date
2021-12-09
Last Posted Date
2024-07-11
Lead Sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Target Recruit Count
648
Registration Number
NCT05151328
Locations
🇨🇳

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.